NCT04355156 2026-04-16
AXMUS-C
Imperial College London
Phase 2 Completed
Clinical Trials
95 trialsNCT05969496 2026-04-13
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT05327686 2026-04-08
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT03297606 2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07123090 2026-03-25
SPARCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07469683 2026-03-13
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Phase 2 Recruiting
NCT06860386 2026-03-06
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Suspended
NCT01409200 2026-03-03
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03839498 2026-03-02
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Columbia University
Phase 2 Active not recruiting
NCT05805501 2026-02-12
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03092856 2025-12-17
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
Phase 2 Active not recruiting
NCT07277972 2025-12-11
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04996823 2025-12-04
Axitinib + Ipilimumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03595124 2025-12-03
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT06962787 2025-11-17
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT03438708 2025-10-02
PADRES
University of California, San Diego
Phase 2 Active not recruiting
NCT07172386 2025-09-16
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT04258956 2025-09-11
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Completed
NCT07159191 2025-09-08
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02597322 2025-04-06
AXIPAN
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT06889649 2025-03-21
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Peking University First Hospital
Phase 2 Recruiting
NCT05256472 2025-03-06
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Akeso
Phase 2 Active not recruiting
NCT04562441 2025-01-10
NPC - AXEL Study : Axitinib-Avelumab
Chinese University of Hong Kong
Phase 2 Completed
NCT05097599 2025-01-08
StrataPATH
Strata Oncology
Phase 2 Terminated
NCT06211114 2024-11-26
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT02639182 2024-11-18
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Phase 2 Completed
NCT06690697 2024-11-15
Combination of Toripalimab and JS004 Therapy for ccRCC
Fudan University
Phase 2 Recruiting
NCT03990571 2024-10-18
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01263769 2024-09-19
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02636725 2024-07-12
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Phase 2 Completed
NCT05420220 2024-05-01
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Recruiting
NCT03472560 2024-04-09
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Pfizer
Phase 2 Terminated
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT02579811 2023-06-29
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05817903 2023-05-08
AxIn
Consorzio Oncotech
Phase 2 Recruiting
NCT05249569 2023-05-03
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT04010071 2023-03-29
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
Peking Union Medical College Hospital
Phase 2 Unknown
NCT01385059 2023-03-07
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02489695 2022-09-06
AXIPAP
Centre Leon Berard
Phase 2 Completed
NCT05263609 2022-08-02
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
Phase 2 Withdrawn
NCT02129647 2021-12-01
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase 2 Completed
NCT02261207 2021-09-28
Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT04995016 2021-08-06
PANDORA
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT04958473 2021-07-12
SAARCC
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03494816 2021-06-30
NAXIVA
Scottish Clinical Trials Research Unit
Phase 2 Completed